Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tampa, Florida 33559


Purpose:

In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and treatment of individuals with HF. Presently, HeartMapp includes physiological modules (PM) that support self- monitoring and exercises that promote heart health, and cognitive modules (CM) that track and enhance cognitive functions. During the first three-months, the investigators will finalize the cognitive training (CT) modules within HeartMapp and release through the quality management system. At the completion of software development, the investigators propose to test the relevant usage and progression variables of the algorithm that will be used to direct engagement with the app. The investigators will conduct a two-arm, open label, pilot clinical trial to examine feasibility and initial efficacy of the HeartMapp (n=20) compared with an attention control condition (n=20) of using CHF Info App (Heart failure (HF) education component of the HeartMapp) for 6-months. The attention control group will have access to HeartMapp at the end of three months and an evaluation at 6-months to assess potential efficacy and long-term engagement with HeartMapp.


Study summary:

Heart failure (HF) is a progressive disease that affects 6.5 million Americans and is projected to reach 10 million by 2020. Presently, treatments for HF are largely comprised of drug therapies targeting pathophysiology and self-administered therapies that require patients to learn, accurately recall and routinely execute complex self-care practices. HF patients are expected to monitor their weight, diet and manage their medications, and are also required to recognize, monitor and report HF related symptoms. However, adopting self-care behaviors are often challenging for patients due to concomitant cognitive impairments, as shown in 30% to 80% of HF patients; a condition which is often complicated by insufficient social support. Multiple studies have shown a direct relationship between cognitive deficits and difficulty with self-care. Thus, there is currently an urgent unmet need for novel patient-centered interventions that are easy to use by older adults with HF that suffer cognitive difficulties and lack social support. In the current application, investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and treatment of individuals with HF. Presently, HeartMapp includes physiological modules (PM) that support self- monitoring and exercises that promote heart health, and cognitive modules (CM) that train participants to enhance cognitive functions. The Posit Science Inc. team of developer and neuroscientists will closely collaborate with investigators at University of South Florida (Drs. Athilingam and Labrador), inventors of the initial version of HeartMapp, to include a clinician-facing dashboard and reporting utility comprised of both PM and CM performance and progress tracking metrics. This Point-of-Care (POC) device will also aid clinical studies of cardiovascular, lung, and blood diseases and disorders by providing continuous monitoring data collected remotely to serve as an open channel between patients and clinicians. A recent usability study of the HeartMapp PM conducted by co-investigator Dr. Athilingam in 25 HF patients was successful; patients found the app easy to use, helpful and engaging. A concurrent pilot clinical trial that examined only CM in 17 HF patients demonstrated that CM improved memory, cognitive speed of processing, and showed trends for improved everyday function and HF self-care. Across all functional outcomes measured, the CM group showed better function post-training relative to controls. Similarly, in our prior research, and in the successful development of related products at Posit Science that demonstrated a core ability to develop multimodal (i.e., assessment and treatment) applications with compelling user experiences that drive strong performance improvements across multiple performance domains. For the current project. The investigators will conduct a two arm, investigator blinded, pilot clinical trial to examine feasibility and initial efficacy of the HeartMapp +cognitive training (CT) compared to an attention control condition who will use the CHF Info App +control games. The study will enroll 40 adults aged 40 and older with a diagnosis of HF. Eligible participants will be randomized to either HeartMapp +CT or an active control condition using the CHF Info App +control games. Both groups will complete follow-up assessments at 3- and 6-months after enrollment. - The primary outcome is to test the feasibility and efficacy of using HeartMapp with CT, which will be quantified by measuring app usage and engagement with the apps. Engagement with CT will be calculated as percentage of participant's who complete at least 20 hours of assigned CT included in HeartMapp. App usability and engagement will be assessed by App access by participants; Accessing App components at least 80% of the days (72 days out of 90-days) will be used to determine app engagement. - The secondary outcomes are improvement in cognitive function and HF self-care. If an effect sizes on Cohen's d of d=0.25 or greater relative to controls for these outcomes, HeartMapp will be considered potentially efficacious. - Exploratory outcomes include improvement in quality of life, global health, medication adherence, heart rate variability and hospital admission. The investigators will calculate effect sizes using Cohen's d on these outcomes to inform future studies.


Criteria:

Inclusion Criteria: Selection of participants is based on their condition HF and is not based on gender or ethnic considerations, although these are expected to reflect the diverse population of the United States; ethnic minorities will be included when available and recruiting efforts will target a balanced enrollment. - Age 40 years or above, - Clinical diagnosis of HF as defined by the International Classification of Diseases (ICD-10 codes) and recent hospitalization for HF, - New York Heart Association (NYHA) classification II-III, - Ability to speak, understand and read English, - Adequate hearing, as determined by response to a pure-tone stimulus at 70 decibels or better for 1 & 2 kHz in each ear, measured using the Welch-Allyn. - Intact vision (visual acuity of 20/50 or better, as assessed by a Snellen chart per standard procedure). Exclusion Criteria: Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation. - Listed for heart transplant as status 1A, - Enrolled in a palliative or hospice care program, - Currently enrolled in another research study, - Previous participation in a cognitive training study - Self-reported vision, hearing, or motor difficulties that would interfere with the ability to complete the study interventions, - Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic brain injury, brain tumor, or a neurological disorder that affects cognition or would interfere with the ability to benefit from the study intervention (e.g., Parkinson disease, multiple sclerosis), or any other unstable medical conditions that is predisposing to imminent cognitive or functional decline (e.g., undergoing chemotherapy or radiation). - Presence of disability (e.g., aphasia) that may prevent them from completing study related activities - Severe depressive symptoms - Evidence of dementia with a score of >=20 in the Montreal Cognitive Assessment, (MoCA) validated for HF.59, 60 While process-based cognitive interventions are not appropriate for dementia, they have been shown effective to remediation cognitive difficulties and mild cognitive impairment (MCI), both of which are prevalent in HF patients


NCT ID:

NCT03827954


Primary Contact:

Principal Investigator
Ponrathi R Athilingam, PhD
University of South Florida

Ponrathi R Athilingam, PhD
Phone: 8139747526
Email: pathilin@health.usf.edu


Backup Contact:

N/A


Location Contact:

Tampa, Florida 33559
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.